Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma.
Colton LadburySavita DandapaniClaire HaoMildred FabrosArya AminiSagus SampathScott GlaserKaren SokolovJekwon YehJohn H BairdSwetha KambhampatiAlex HerreraMatthew G MeiLiana NikolaenkoGeoffrey ShouseLihua E BuddePublished in: Cancers (2023)
BT did not appear to compromise outcomes with respect to response rates, disease control, survival, and toxicity. The patients with limited disease treated with RT had favorable outcomes.